Citius Pharmaceuticals, Inc. Board of Directors

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Mr. Leonard L. Mazur

Mr. Leonard L. Mazur

Co-Founder, CEO, Chairman & Secretary

Dr. Alan Lader Ph.D.

Dr. Alan Lader Ph.D.

Senior VP and Head of Clinical Operations & Quality Assurance

Mr. Gary F. Talarico

Mr. Gary F. Talarico

Executive Vice President of Operations

Dr. Myron S. Czuczman M.D.

Dr. Myron S. Czuczman M.D.

Executive VP & Chief Medical Officer

Mr. Dhananjay G. Wadekar

Mr. Dhananjay G. Wadekar

Senior Vice President of Business Strategy

Mr. Myron Z. Holubiak

Mr. Myron Z. Holubiak

Co-Founder & Executive Vice Chairman

Mr. Jaime Bartushak

Mr. Jaime Bartushak

Chief Business Officer, CFO & Chief Accounting Officer

Mr. Kelly Creighton Ph.D.

Mr. Kelly Creighton Ph.D.

Executive Vice President of Chemistry, Manufacturing & Controls

Mr. Nikolas Burlew

Mr. Nikolas Burlew

Executive Vice President of Quality Assurance

Ms. Ilanit Allen

Ms. Ilanit Allen

Vice President of Investor Relations & Corporate Communications

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.